Orano Med Appoints Matthew Fyfe as Chief Scientific Officer

Frederic Desdouits, Chief Executive Officer of Orano Med, said: “Matthew’s background will be invaluable in fully leveraging our in-house R&D capabilities. He will lead our scientific research centers in France and the US, accelerating the discovery and optimization of new drug candidates and moving them into the clinic. Matthew has built a strong track record of taking drug discovery programs from early research through to clinical stage. On behalf of the whole team, I would like to welcome Matthew to Orano Med, and I look forward to working with him.”

Dr. Fyfe joins Orano Med from Outrun Therapeutics, where he served as Chief Scientific Officer. Previously, he has held senior leadership positions at several biotech companies, including Storm Therapeutics, Sitryx Therapeutics, TopiVert Pharma, Oryzon Genomics and Prosidion.

Matthew Fyfe, Chief Scientific Officer of Orano Med added: “With its leading position in lead-212-based targeted alpha therapies, Orano Med is pioneering a new segment of the radiopharmaceutical field. With multiple products in clinical and late preclinical development, this is a great moment to join the Company. I am excited to bring a fresh perspective to the existing strategic vision to help drive these promising cancer drug candidates forward so that we can ultimately offer new treatment options to the patients who need them.”

Dr. Fyfe holds a BSc from the University of Glasgow, an MA from Columbia University and a PhD from the University of Birmingham, which was followed by postdoctoral research at UCLA. He is a Chartered Chemist and Fellow of the Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on more than 100 published patent families.